Gerstenfeld LC, Sacks DJ, Pelis M, Mason ZD, Graves DT, Barrero M et al (2009) Comparison of the effects of the bis- phosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bon
Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: A review of preclinical and clinical data 2012, Clinical Therapeutics Citation Excerpt : The most relevant animal model for postmenopausal osteoporosis is perhaps the adult OVX nonhuman primate, which...
which then migrates to the nucleus and inducescyclin D1transcription. On the other hand, Id2 translocates into the nucleus and reduces expression of the cell cycle inhibitor p21. Altogether, these molecular events result in increased proliferation and survival of mammary epithelial ...
NCT00321464 phase III Advanced breast cancer 2046 Denosumab vs. zoledronic acid Time to first on-study SRE NCT00556374 phase III Nonmetastatic breast cancer on aromatase inhibitor therapy 2800 Denosumab vs. placebo Time to first fracture NCT00330759 phase III Advanced solid organ malignancy...
Estrogen is critical for skeletal homeostasis and regulates bone remodeling, in part, by modulating the expression of receptor activator of NF-κB ligand (RANKL), an essential cytokine for bone resorption by osteoclasts. RANKL can be produced by a variet
International Journal of Molecular Sciences Article The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells Masanobu Tsubaki 1,†, Shiori Seki 1,†, Tomoya Takeda 1, Akiko Chihara 1, Yuuko Arai 1, Yuusuke Morii 1,2, Motohiro Imano 3, Takao Satou...